Top 5 Targeted Therapy Drugs and How They Work

Recent Trends

Oncology has shifted from broad cytotoxic chemotherapy toward molecularly guided treatments. Over the past decade, the number of FDA-approved targeted therapies has grown significantly, with many now used as first-line options for specific tumor types. The trend is driven by deeper understanding of genetic mutations and signaling pathways, enabling drugs that interfere with precise molecular abnormalities rather than killing all rapidly dividing cells. Clinical practice increasingly requires tumor profiling to match patients with the most appropriate agent.

Background and Key Examples

Targeted therapy drugs are designed to interfere with specific molecules involved in cancer growth and survival. Unlike chemotherapy, they aim to spare normal tissues. The following five drugs represent established examples across different cancer types and are often referenced when discussing targeted approaches:

• Imatinib (Gleevec) – Targets the BCR-ABL fusion protein in chronic myeloid leukemia. It blocks the abnormal tyrosine kinase signal that drives uncontrolled proliferation.
• Trastuzumab (Herceptin) – A monoclonal antibody that binds to HER2 receptors on breast and gastric cancer cells, preventing growth signals and marking cells for immune attack.
• Erlotinib (Tarceva) – Inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, commonly used in non-small cell lung cancer with specific EGFR mutations.
• Vemurafenib (Zelboraf) – Selectively blocks the mutated BRAF V600E kinase in melanoma, halting downstream MAPK pathway signaling.
• Palbociclib (Ibrance) – A CDK4/6 inhibitor that arrests cell cycle progression in hormone receptor-positive breast cancer when combined with endocrine therapy.

User Concerns and Questions

Patients and clinicians often compare targeted therapies against standard chemotherapy. Common concerns include:

• Side effect profiles: While generally less severe than chemotherapy, targeted drugs can cause fatigue, rash, diarrhea, or more specific toxicities such as cardiac dysfunction (trastuzumab) or interstitial lung disease (some tyrosine kinase inhibitors).
• Resistance development: Many tumors eventually bypass the drug’s target through secondary mutations or alternative pathway activation, requiring second-line agents or combinations.
• Cost and accessibility: Targeted therapies are often expensive, and insurance coverage depends on biomarker testing requirements. Not all health systems have equal access to molecular profiling.
• Eligibility: Only patients whose tumors harbor the specific mutation or overexpression benefit. Testing availability and turnaround time can delay treatment initiation.

Likely Impact on Treatment Paradigms

The integration of these drugs has shifted treatment from empirical regimens to biomarker-driven selections. For example, routine EGFR testing in lung adenocarcinoma is now standard, and HER2 testing in breast cancer dictates the use of trastuzumab. This approach reduces unnecessary toxicity in non-responders and improves outcomes in molecularly defined subgroups. However, the need for repeat biopsies and liquid biopsies to monitor resistance is becoming common practice. The overall impact is a more individualized yet complex decision-making process requiring multidisciplinary teams.

What to Watch Next

Emerging developments include next-generation inhibitors for resistant mutations (e.g., osimertinib for EGFR T790M), bispecific antibodies, and antibody-drug conjugates that combine targeting with cytotoxic payloads. Combination therapies—such as CDK4/6 inhibitors with endocrine therapy—are expanding to earlier disease stages. Additionally, liquid biopsy technologies are improving real-time noninvasive monitoring of targetable alterations. Continuous updates to clinical guidelines and payer policies will determine how quickly these advances reach broad patient populations.